WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update…Read More
ProKidney Reports Second Quarter Financial Results and Recent Corporate Highlights
